🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
25.89
-0.28 (-1.07%)
Nov 20, 2026, 12:34 PM EST - Market open
← View all transcripts

UBS Global Biopharma Conference 2026

Nov 16, 2026

Summary

The darovasertib NDA was filed under RTOR with a strategy seeking HLA-A2-independent use; PFS was viewed as sufficient for accelerated approval, with interim OS guided for mid-2027. PRMT5 combination data were targeted for 2027, while DLL3 Phase III trials were planned to start by year-end 2026.

Michael Yee
Senior Biotechnology Analyst, UBS

All right, fantastic. If we are ready to go, thank you so much for joining us on our next session. I am Michael Yee, Senior Biotechnology Analyst here at UBS, and we are excited to have the Chief Executive Officer of IDEAYA Biosciences here, Yujiro Hata, with us. IDEAYA is an exciting time right now because the company is on the brink of filing and getting potential approval for their lead drug, I say daro, but darovasertib, for metastatic uveal melanoma, a small molecule with tremendous efficacy and positive phase II results.

That may happen in 2027, on the brink of your first approval. In addition, there is so much pipeline to talk about, I am going to have to limit it in our 25-minute discussion because there is not enough time. You are hosting an R&D analyst event later today as well, so we get a little preview of that today. Without further ado, maybe, Yujiro, you could set the table for us first to just obviously talk about the most important things going on at IDEAYA with, perhaps we will hear more later at the R&D day, but set the table for us a little bit about your current pipeline.

Yujiro Hata
CEO, IDEAYA Biosciences

Well, great. First, thank you, Mike, for hosting us, and also congratulations to UBS on the inaugural event in London this week. IDEAYA Biosciences, as you mentioned, 2026 has been a transformational year for us. We filed our first NDA, also reported our top-line results in an oral presentation at ASCO several months ago. We also did recently announce the advancement of DLL3 TOP1 ADC into phase III registrational studies, as well as positive second-line overall survival data in small cell lung cancer at ESMO, just here recently. Mike, as you noted, the updates are going to continue. We have our first London R&D day later this afternoon at 5:00 P.M. London time, where we will showcase what we believe is a very deep pipeline in MTAP and CDKN2A. Hopefully a lot to talk about today, Mike. We look forward to the discussion.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay. We will preview it a little bit here in our session. But coming to the primary lead program, daro, for metastatic uveal melanoma, you filed the NDA. The filing presumably is for HLA-A2 negative patients, of which the phase III was enrolled and completed in. So talk about where you are in that filing, when would be the expected approval, and what do you expect the approval to look like?

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah. The NDA has been filed. We noted that that happened in the third quarter. It was towards the end of the third quarter. That was also filed under RTOR, so a rolling review submission process of the NDA. Our focus on the phase III randomized study was on the HLA-A2 negative population in the first-line setting of metastatic uveal melanoma. We have noted, based on our recent disclosures, that based on the mechanism of action as well as the data that we had presented, we do believe darovasertib is relevant irrespective of HLA-A2 status. That is how we did proceed with the NDA filing, with that specific mindset in place.

Michael Yee
Senior Biotechnology Analyst, UBS

When you file it, and I've never filed an NDA, but you write out an indication, does it say HLA-A2 negative in that exact filing indication?

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah. As part of our NDA submission, the strategy that we are advancing is a focus on irrespective of HLA-A2 status.

Michael Yee
Senior Biotechnology Analyst, UBS

Irrespective. Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah. But we would want to emphasize that we appreciate this will be a review issue with the FDA. Second is that we will, in either scenario, have an NCCN strategy in place for both the negative and the positive population.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay. Have you completed the rolling NDA, or maybe I might hear about that later today, I don't know. But what is the estimated PDUFA date and timing for approval?

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah. So we will learn on the PDUFA date here relatively soon.

At the time of NDA acceptance, we do anticipate it will be likely in that first half of next year timeframe.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay. Okay. When that occurs, you have filed for approval irrespective of HLA status. Most people on Wall Street would say, "Okay, wait a second." Just for those who may not know all the numbers, the reason why we are asking about this is because HLA-A2 negative is around 50/50. You might give me a different number, but it is around 50% of the target population, whereas Immunocore, another company that is actually here at this conference as well, is approved in HLA-A2 positive, the other 50%. While your indication would be going after a market that is not directly competing against Immunocore, you do believe that you could get approval for both populations and therefore double your opportunity, double, because it is in the other subgroup. Most people, investors do not know about that, but that was not what the study was enrolling. That was HLA-A2 negative.

What would be the reason, and why would you say that you could get approval in both?

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah. Also, Michael, on the question around the prevalence or frequency of HLA-A2 negative versus positive, we do believe the majority of the population is HLA-A2 negative.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

We believe it's likely in that 60/40 to two-thirds, one-third range.

Michael Yee
Senior Biotechnology Analyst, UBS

Right. Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

Second, in terms of our reason why we believe this therapy is relevant to the broader population of metastatic uveal melanoma is because of its mechanism of action. As a reminder, over 95% of this patient population, we believe, does have an activating mutation of GNAQ/11, which turns on the PKC signaling pathway. This is not a MOA that's specifically linked to HLA-A2 status.

Michael Yee
Senior Biotechnology Analyst, UBS

Right.

Yujiro Hata
CEO, IDEAYA Biosciences

That's really probably the—

Michael Yee
Senior Biotechnology Analyst, UBS

That is a factor of the currently approved drug KIMMTRAK—

Yujiro Hata
CEO, IDEAYA Biosciences

—Correct.

Michael Yee
Senior Biotechnology Analyst, UBS

—is a TCR-based drug, which would have to do with whether or not your HLA status matches up with the drug in order to bind, in order to work. Yours is a small molecule. That doesn't have anything to do with that.

Yujiro Hata
CEO, IDEAYA Biosciences

Exactly. Right. Then also, the data that we presented at ESMO.

Michael Yee
Senior Biotechnology Analyst, UBS

Right.

Yujiro Hata
CEO, IDEAYA Biosciences

I believe corroborates that point, that the HLA-A2 status is not linked to the mechanism of action that darovasertib specifically addresses.

Michael Yee
Senior Biotechnology Analyst, UBS

And how many patients were treated in that study?

Yujiro Hata
CEO, IDEAYA Biosciences

We had roughly about 100 patients worth of data. Roughly 20% of that was in the first-line setting.

Michael Yee
Senior Biotechnology Analyst, UBS

How many patients were in the second line, excuse me, in the HLA-negative phase III?

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah. The HLA-A2 negative, as a randomized study, we had roughly in that 400-patient range.

Michael Yee
Senior Biotechnology Analyst, UBS

200.

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah.

Michael Yee
Senior Biotechnology Analyst, UBS

200 have been treated and have randomized controlled data, approximately 100 in HLA-A2 positive, of which 20% of it, so 20, were in the HLA-A2 positive group. There is safety data, that is important, efficacy data that aligns with the same overall response rate and same PFS and general overall survival cross-trial comparison, open label. It generally aligns with that.

Yujiro Hata
CEO, IDEAYA Biosciences

Yes, it does. Generally aligns with that. Appreciate one is a randomized study. Obviously, also you have to think about the ratio of the randomization for that randomized study.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

Correct. I think big picture related to PFS obviously the OS data, single-arm data versus randomized data, so there are going to be some differences there. Big picture, we do think the data negative and positive are generally very similar.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay. Assuming we do get approval, just sticking with the near-term commercial opportunity, you think it is 60%, whereas KIMMTRAK may be 40%-50%. Now, I cover Immunocore, and Immunocore's KIMMTRAK launch was quite robust out of the gate, just to be fair. Very strong launch, relatively high-priced drug, but of a strong survival benefit, and has approvals and reimbursement around the world a lot of countries, and is on pace to do approximately 400 and something million dollars.

Do you believe that your launch would be no different in the U.S. because your price of your drug would probably be somewhere in the similar vicinity range? You have survival data too, although that survival is not completed yet, so we need to answer that. But that the launch of that drug should be no different. You have a small molecule, they had an infusion. You would argue your drug is even easier to administer. So, what would you say about their launch and your launch?

Yujiro Hata
CEO, IDEAYA Biosciences

Look, I think there are several parallels to KIMMTRAK that we have that I would say gives us confidence in this upcoming projected commercial launch. First is we are seeking first-line approval, similar to KIMMTRAK, and obviously that is going to have certain advantages. Also, as a reminder here, remember, in this case, the indication is the diagnostic. So, we do not have a situation where, at least for the mutation at GNAQ/11, there is not a diagnostic that we need. As well to identify these patients. Thus far, in addition to getting frontline approval, we believe the other treatment options are not effective in relation to the data we saw based on the hazard ratio we reported for PFS, and the response rate was approximately six times beyond what we saw in the control arm. Based on those set of facts, we do anticipate a strong launch.

Michael Yee
Senior Biotechnology Analyst, UBS

When KIMMTRAK was approved, I recall that they had an OS completion. Your phase III has completed PFS a nd that data has been presented at ASCO. But the survival is still maturing. There is a trend in survival, I think you have said, but it has not completed. To what extent does survival play any role in the approvability of the drug? Or the fact that approval survival may not be in the label? I am not sure that a doctor would or would not prescribe the drug because of survival, because there are no options, frankly, and the PFS is fantastic. But does FDA need survival for approval?

Yujiro Hata
CEO, IDEAYA Biosciences

For accelerated approval, based on the endpoints that we reached in alignment with the FDA, we do believe PFS is sufficient for accelerated approval. Mike, as you mentioned, OS will be upcoming. The guidance we've given is an interim OS readout in the middle of next year. That continues to be the guidance that we have. But no, we do feel confident in the data we have based on the very robust hazard ratio that was reported. PFS as the aligned endpoint for accelerated approval.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay. Yeah, it's accelerated approval. Survival would serve for confirmatory.

Yujiro Hata
CEO, IDEAYA Biosciences

Correct.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay. Another thing to think about in terms of the profile of the drug and the launch and comparing it to the revenue opportunity that KIMMTRAK has.

Again, KIMMTRAK is doing hundreds of millions of dollars as an HLA-A2 positive. You think your market's a little bit bigger, 60%. Price of the drug could be similar. Again, Wall Street analysts are modeling it the same, yet you could be 2X because you could get use in HLA-A2 positives. If you don't get the broad label, and we'll see, would there be patients who could still access it through NCCN guidelines? That would be an opportunity. Would that take time for that to happen, or would that be pretty quick?

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah, assuming that we get approval and commercial launch, our plan would be to sequence our strategy and implementation of that in terms of NCCN guideline process in fairly proximal nature to the anticipated approval. We do believe, because this is an area of unmet need, that there could be an opportunity for a fairly near-term review as part of that under NCCN. That's our at least current thinking right now.

Michael Yee
Senior Biotechnology Analyst, UBS

I mean, it's a little unclear to me how fast this happened, but could that be something that happens in calendar 2027?

Yujiro Hata
CEO, IDEAYA Biosciences

Yes.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

Yep.

Michael Yee
Senior Biotechnology Analyst, UBS

That could be in NCCN guidelines. Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

Well, the process that we would initiate is part of that. Yeah, I think the question—

Michael Yee
Senior Biotechnology Analyst, UBS

Yeah, like it doesn't happen until after you get approval.

Yujiro Hata
CEO, IDEAYA Biosciences

Correct.

Michael Yee
Senior Biotechnology Analyst, UBS

Then you initiate the process. I am not an expert in how long that process takes, because it is like a working group, the NCCN, that has to do that, and they only do it like once or twice a year or something like that.

Yujiro Hata
CEO, IDEAYA Biosciences

Yes, so that process we anticipate will be several months. I think there, the question of the annual versus an ad hoc review. We do think some of the parameters to consider is that this is an area of very high unmet need.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay. Yes. All right. Look forward to that opportunity and approval. Again, I always just say, we are going to talk a little bit more about that later today and the opportunity. So we are just giving a little preview of that. The second thing that I have been very excited about, and I am sure you are going to talk about it later today too, is the fact that you have had a bunch of press releases this summer recently about your PRMT5. So we are going to talk about MTAP tumors. Your PRMT5 could be a best in class, and it is currently in phase I testing.

But importantly, you have also announced in these two press releases a collaboration with Roche to combine your PRMT5 with their pan-RAS and with their G12D. So Roche has got some pretty awesome drugs, and you have a third drug that could be synergistic. Talk about your PRMT5. People are familiar with Tango's product. Do you think your product is as good as Tango's product? When are we going to get some data?

Yujiro Hata
CEO, IDEAYA Biosciences

We will share some clinical data in a few hours here later this afternoon that will include human PK.

Michael Yee
Senior Biotechnology Analyst, UBS

Human PK.

Yujiro Hata
CEO, IDEAYA Biosciences

Safety data, as well as human pharmacodynamic data.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

We will anticipate we will have some patient case studies as well that we will be able to share. Our view is that we do believe we have a potential best-in-class PRMT5 inhibitor. Basically for us, the key parameters for that, Mike, as you know, first is that we do believe having a clean drug-drug interaction profile, in particular against CYP3A4, is critical to fulfill that criteria for best in class. A big reason for that is we believe PRMT5 is largely a combination agent, specifically in the indication of pancreatic cancer, in particular with pan-RAS, with KRAS G12D. We recently also announced our new candidate earlier today related to CDKN2A IDE101, which we anticipate will be in the clinic first half of next year.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

The reason why this is important is that the majority of these targets that we just mentioned, at least the molecules that we are aware of, the metabolism path is largely mediated through CYP3A4. Now, from a drug-drug interaction perspective, we do not believe this is just about pan-RAS, but all these other agents that a PRMT5 inhibitor may want to be combined with, including standard of care chemotherapy in pancreatic cancer, which CYP3A4 plays a key role, as well as you know, con meds that these patients may be on, where you also have to consider CYP3A4. So we do think that is a central TPP to have a best-in-class inhibitor. Second is, we believe CNS penetrance is not a favorable profile, because we do not believe there is a benefit, but could introduce a liability related to CNS-related tox.

Finally, third is MTA-cooperative selective binding versus SAM-cooperative, which we believe should translate into safety and what type of myelosuppression your molecule may or may not be seeing. That is some of the data that we will share here in several hours.

Michael Yee
Senior Biotechnology Analyst, UBS

In order to show lack of drug-drug interactions, what would you need to see? You need to basically show in combination that the two drugs in a phase I do not have changes in PK. The only way to do that is that you somehow took your own drug and dosed it in someone who else who had another drug that had the same pathway. One of those would be potentially pan-RAS drugs. So when you dose daraxonrasib from Revolution Medicines and you dose with Tango's PRMT5, they do show PK changes, and that is very clear that that is being due to an interaction. Would you need to dose your drug with daraxonrasib in order to show that?

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah. The view here, Mike, is that we've already been generating clinical data in combination with another molecule that is also CYP3A4 mediated including IDE397, our MAT2A inhibitor. That's some of the data that we plan to share here this afternoon.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

We feel we've already seen data that supports this notion that we mentioned about not having that type of drug-drug interaction liability related to CYP3A4.

Michael Yee
Senior Biotechnology Analyst, UBS

Is that literally should be the only de-risking factor to show that that should not impact daraxonrasib if it was. I mean, you could dose some patient with daraxonrasib. I mean, the drug is out there, so technically you could go find some patients and do that pretty quickly. But just like conceptually, I am not an expert in DDIs, but if you, other than dosing with those patients, which would be helpful data too, you are saying you have dosed with another CYP3A inhibitor and you do not see interaction, so there you go.

Yujiro Hata
CEO, IDEAYA Biosciences

I think the data we have generated is an important first step already, that we have already answered the question. We will be generating data with Roche on pan-RAS here shortly, so we should be dosing our first patient by the end of the year. We do know that several of these molecules that are tri-complex inhibitors via cyclophilin, the chemistry has some similarities across several of these molecules in the clinic. So, we do think once we have that data with Roche, we will be able to validate that as well. But we already have early clinical read that it does not appear we are at least driving a CYP3A4 liability with other drugs that we know are mediated through [CYP3A4].

Michael Yee
Senior Biotechnology Analyst, UBS

On one hand, it is one step to show that you could have no drug-drug interactions with another major blockbuster drug. Let us all be fair, daraxonasib is set to be a pretty big drug. If you could show that in combination, that would be one de-risking effect because the other one does seem to have some of those effects. The other is to show it that you could do that in combination with another pan-RAS, which could be an exciting competitor to daraxonasib, which is Roche's pan-RAS.

Roche has a pan-RAS, we think, although you could perhaps agree or not agree that they've treated a lot of patients with their pan-RAS, so they have data internally. They think it's a pretty good pan-RAS, could be as good as daraxonasib, behind, but could be similar, and yet you're going to be in combination with that. Have you dosed patients together with that drug in the clinic in phase I? Has that started or it's about to start?

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah, so that dosing is going to be here in the very near term.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

We do believe that we'll be able to dose our first patient by the end of the year.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

Be able to answer that question, and we do think that will be an important indicator for other pan-RAS inhibitors like daraxonasib as well. The one important piece, Mike, I think that we would emphasize, we also did do preclinical evaluation of several of the PRMT5 inhibitors in the clinic, and our view is based on the data we generated, was some of the drug-drug interaction that was reported would have been anticipated based on the preclinical data that we assert. I would highlight here, there's two aspects of DDI that you want to think about. One is the reversible IC50s for drug-drug interactions, including CYP3A4. The other is irreversible, which is also called time-dependent inhibition.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

And you need to look at both to really have a sense of the potential DDI liability. Our view is the data that was reported was anticipated based on the preclinical evaluation, which is also why it gives us confidence that ours should have a very favorable DDI profile based on that preclinical support that it was anticipated. This was not sort of a finding that was outside of what would have been anticipated.

Michael Yee
Senior Biotechnology Analyst, UBS

Let me explore that a little bit.

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah.

Michael Yee
Senior Biotechnology Analyst, UBS

So again, the idea that PRMT5, such as Tango, in combination with RevMed's pan-RAS, clearly the efficacy is very exciting. That is great. This is why there is a lot of Wall Street enthusiasm around this pathway, and that by taking PRMT5 plus pan-RAS, we get much higher efficacy and not a lot of added toxicity. Fantastic. If you can show that same type of efficacy and good side effect profile and not have to dose down daraxonasib, that would be great.

Perhaps we get similar or better efficacy because you are dosing down one of the key drivers of that. That would be great. It is the concept that you could also dose with chemo.

is what you are saying, because there are first-line studies that I guess would happen, or in combination with the G12D and a pan-RAS and your drug in like a triple all-oral regimen. Is that the idea?

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah. I think the commentary—

Michael Yee
Senior Biotechnology Analyst, UBS

Some people think that the DDI issues, and again, this could be coming from the competitor, is not a big deal.

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah. I think the CYP3A4 piece, I think the main point there was that that would be relevant beyond pan-RAS, right? It would also impact G12D, our CDKN2A molecule we mentioned, as well as other standard care agents like chemotherapy that are also known to be mediated through CYP3A4. Big picture, our view is that it will make life simpler to be able to have a molecule that you do not have to consider the drug-drug interactions. I think just the other part, this is really just from our perspective, as you know, clinical development is a long path, right? You are going to have to go into larger patient data sets, larger registrational trials. At least our view in terms of a more favorable profile would be ideally one without a drug-drug interaction.

We think that is independent of PRMT5, but that is more of a general statement in the pharma circle, general industry.

Michael Yee
Senior Biotechnology Analyst, UBS

Since this is a pretty big value creation opportunity for you, do you think we could get combination data with your PRMT5 and Roche's pan-RAS in 2027? That could be a major medical conference in Chicago. I do not know, but—

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah, I mean—

Michael Yee
Senior Biotechnology Analyst, UBS

—possible.

Yujiro Hata
CEO, IDEAYA Biosciences

—Yeah, I think having an update on clinical data next year should be the objective. We anticipate that the initial cohort, based on the dose we have cleared for monotherapy for PRMT5 as well as our current plan to start the pan-RAS inhibitor at the Roche expansion dose. We anticipate that first cohort may very well be the expansion dose.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

This is not going to be a very long dose escalation. It may be one cohort.

Michael Yee
Senior Biotechnology Analyst, UBS

Right.

Yujiro Hata
CEO, IDEAYA Biosciences

We do anticipate to see fairly meaningful activity at that cohort.

Michael Yee
Senior Biotechnology Analyst, UBS

Think about it, right? If Roche has been running the pan-RAS at different doses, they are finding a dose that is efficacious and reasonably well tolerated, that is their dose that they are excited about, whatever dose that is. You would just take, in combination, your drug and add it onto that in an expansion cohort. They are going to do monotherapy, and they would do combination at that expansion cohort. Pick a random, like 400 mg, I am just picking a number. I do not know the doses.

Yujiro Hata
CEO, IDEAYA Biosciences

Yep.

Michael Yee
Senior Biotechnology Analyst, UBS

It should be pretty quick because it is like one cohort. You should be able to know what is happening.

Yujiro Hata
CEO, IDEAYA Biosciences

Exactly.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

Yep.

Michael Yee
Senior Biotechnology Analyst, UBS

All right. I hope to see that data and the monotherapy data because Roche talks a little bit about it. The idea, if they do have a competitive one, would be exciting for you. Does this also apply to lung cancer as well? Many people think the PDAC market is running away with daraxonasib, just to be fair. RevMed just did record numbers in the first month, and Tango is already trying to initiate a phase III in PDAC. People feel like the PDAC market opportunity is running away down the field, and yet Roche and you guys do not have any data in PDAC yet. Does lung cancer, does this apply to lung cancer as well?

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah, so it can apply to lung cancer, Mike. I would say our top priority is pancreatic cancer, primarily because we believe it represents about 40% of that population.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

Second, we do continue to believe that a first-line strategy in frontline PDAC still remains very open, especially related to MTAP and RAS—

Michael Yee
Senior Biotechnology Analyst, UBS

Right.

Yujiro Hata
CEO, IDEAYA Biosciences

—intersection, which is substantial. Lung cancer is going to be a smaller population, so you want to take roughly 15%. And divide it by three, so it is about 5% of lung cancer, because you have to think about the co-alteration population. But clearly an opportunity that could be pursued as well.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay. I agree. So first-line PDAC in combination would be an obvious—

Yujiro Hata
CEO, IDEAYA Biosciences

Correct.

Michael Yee
Senior Biotechnology Analyst, UBS

—study that you would want to get going as soon as possible. Like I said, Tango is trying to get it going, but they haven't dosed patients yet in phase III. Last one in our last couple minutes. I appreciate, and you will go through more of this later this afternoon. The DLL3 antibody drug conjugate landscape and the DLL3 overall is an exciting area. Amgen has been doing quite well with tarlatamab in small cell lung cancer, and they are also in first-line maintenance. Great for Amgen.

It is looking to be a multi-billion dollar drug. We cover that stock. They have been doing great. Meanwhile, Zai Lab has been putting up some data, and they have started, they are in a pivotal randomized study, and they are going to report out data by summer of next year. Where are you with your DLL3, and can you get that going as soon as possible and catch up to all these players?

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah, so Mike, DLL3, another great target. We believe ESMO established DLL3, we believe, as the most validated target in small cell lung cancer as well as neuroendocrine carcinoma-

Michael Yee
Senior Biotechnology Analyst, UBS

Okay.

Yujiro Hata
CEO, IDEAYA Biosciences

Through several independent datasets, including the DeLLphi data and frontline maintenance from IMDELLTRA, our peers' data as well as ours, where we reported second-line overall survival of over 14 months in the small cell lung cancer setting, which we think is quite exciting. In addition, Mike, in terms of where we are, we did announce recently that our plan to start two registrational phase III studies by the end of the year, including in the relapsed setting of small cell lung cancer post-IMDELLTRA which we think is an important point of differentiation, especially now with IMDELLTRA moving into frontline maintenance. And then second, in refractory neuroendocrine carcinoma. We will be providing more updates here very shortly on what our specific trial design plans are in NEC.

Michael Yee
Senior Biotechnology Analyst, UBS

Just to be clear, you believe that in second-line small cell lung cancer, second-line plus, if you fail tarlatamab, which is most of the population over the next five or 10 years, that your drug, although it is the same target of DLL3, different mechanism of action, that they have not lost the antigen and that your drug should still have plenty of efficacy in a single-arm pivotal study or a randomized study?

Yujiro Hata
CEO, IDEAYA Biosciences

In later-line small cell lung cancer, we believe that likely you would need to pursue a randomized study. In the post-IMDELLTRA setting. In the NEC setting, that answer may be different. That's what we'll give more color on here shortly in the next several days. On our view on that. On post-IMDELLTRA, post-DLL3 TCE, we do believe you can follow it with another DLL3 agent. We don't believe there's data out there that notes that lowering the expression of DLL3 is going to be a mechanism that we need to be concerned about. Second is that we now are building a growing dataset in the post-IMDELLTRA setting, and we believe we're seeing a very robust response rate.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay. We think there's limited evidence yet. The science should be there, but we don't have a lot of data. This is why when we're going into phase III, we're not totally sure exactly what the response rates are going to be. So we're trying to be probably keynote, but I'm not exactly sure what the response rates are going to be. Okay. Lastly, do you plan to have a first-line strategy or some sort of combination with a TCE? That's what your other competitor is trying to do, and this is a bigger market opportunity. Is that something you'd like to try and do?

Yujiro Hata
CEO, IDEAYA Biosciences

Yeah. No, thank you for that question. So yeah, so frontline small cell lung cancer definitely is in scope for us. In terms of a high priority. We want to be thoughtful that we are doing a trial that we have confidence in terms of doing it with a differentiated combination. We do believe in the frontline small cell lung cancer setting that the opportunity is primarily in the induction settings based on the recent IMDELLTRA data and maintenance. So I would say we do have interest in several mechanisms, including T-cell engagers, that will not surprise you, as well as bispecific IO. So all we can say is that we are having several conversations on this front, and hopefully you will hear from us more on what our frontline plans are in the future.

Michael Yee
Senior Biotechnology Analyst, UBS

Okay. Thank you very much. Look forward to all the developments in 2027. Obviously, again, R&D Day later today, so everyone should tune in to that, and look forward to great progress. So thank you very much, Yujiro.

Yujiro Hata
CEO, IDEAYA Biosciences

Great. Thank you so much, Mike, for the time.

Michael Yee
Senior Biotechnology Analyst, UBS

Thank you.